Probi today announces a research collaboration with the Global BHP BrainTrust and FINGERS Brain Health Institute (FBHI) aimed at reducing dementia risk in women, who account for two-thirds of Alzheimer’s cases. The collaboration is part of the planned FINGERS Plus for Women study.
"We are thrilled to be part of the FINGERS Plus for Women initiative. This collaboration represents a significant step forward in our commitment to advancing brain health and improving everyday life for people worldwide. By combining our expertise in probiotics with the innovative research approach of the Global BHP BrainTrust and the Fingers Brain Health Institute, we aim to make a significant impact on cognitive health and well-being," says Anita Johansen, CEO of Probi AB.
Probi AB (publ), a global leader in probiotics, and the Global BHP BrainTrust, a renowned advisor and research organization specializing in brain health, are excited to announce the intention to collaborate on the FINGERS Plus for Women initiative together with the Fingers Brain Health Institute (FBHI) founded in 2019 by Professors Miia Kivipelto and Maris Hartmani. FBHI drives, coordinates, and supports the continued clinical research that builds on the original FINGER study1, which showed that lifestyle factors have significant relevance in the prevention of cognitive decline.
The goal is to advance and expand the multi-domain FINGER model for preventive lifestyle interventions, exploring new modifiable risk and protective factors such as stress, sleep, education, music, diet, and the microbiome. Thus, providing deeper insights into how microbiome intervention, e.g. changes in the body’s ecosystem of microorganisms, along with other protective factors, can collectively influence cognitive function and mental well-being in women.
The initiative is driven by the growing recognition of the critical role that lifestyle factors and the microbiome play in brain health. According to the latest evidence 45 percent of all dementias are likely linked to modifiable risk factors creating great potential for prevention2. This research has the potential to deliver transformative impact, including the development of targeted interventions to enhance brain health and prevent cognitive decline. The findings will contribute to a broader understanding of personalized health strategies, ultimately improving the quality of life for women worldwide.
For more information about Global BHP BrainTrust please visit www.globalbhptrust.com
1 Ngandu, Kivipelto, et al., The Lancet, Volume 385, Issue 9984, 2255 – 226 (2015)
2 Livingston et al., The Lancet, Volume 404, Issue 10452, 572 – 628 (2024)
For more information, please contact:
Anita Johansen, CEO, Probi AB, E-mail: anita.johansen@probi.com
Christina Vegge, VP R&D, Probi AB, E-mail: christina.vegge@probi.com
ABOUT PROBI
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of 628 MSEK in 2023. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,400 shareholders on December 31, 2023.
